Exelixis Q4 revenue $599M, diluted EPS $0.88; cabozantinib franchise up 17% in FY2025

EXELIXIS, INC.

2025-FY EPS reported $2.78 revenue$2,320,126,000

Q4 2025 total revenue $598.7M vs $566.8M YoY; GAAP diluted EPS $0.88 vs $0.48.
FY2025 net product revenue $2.123B, up from $1.809B, driven by cabozantinib volume growth.
GAAP net income $782.6M in FY2025 ($2.78 diluted EPS); non-GAAP $869.5M ($3.08 diluted EPS).
R&D expenses fell to $825M (down 9.4% YoY); SG&A rose 5.4% to $518.7M.
NDA for zanzalintinib in mCRC accepted; STELLAR-303/304 readouts and trials expected in 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.